BostonSight is a nonprofit healthcare organization that advances the treatment of diseased or damaged corneas and dry eye.

Our ongoing commitment to research and achieving optimal patient outcomes through innovative scleral lens design, education, and technology have saved the sight of thousands of people around the world.

VISION: A world where no one suffers loss of sight from diseased or damaged corneas and dry eye.

MISSION: To improve quality of life by transforming the understanding, treatment, and care of the ocular surface.

Clinicians

Daniel C. Brocks, MD
Chief Medical Officer

Karen G. Carrasquillo, OD, PhD, FAAO, FSLs, FBCLA
SVP, Clinical and Professional Affairs

Alan Kwok, OD, FAAO, FSLs
Director of PROSE Network Clinical Relationships

Bita Asghari, OD, FAAO, FSLs
Associate Director of Clinical Education

Chirag Patel, OD, FAAO
Associate Director of Innovative Technologies

Senior Staff

Sara Yost, MBA, President and Chief Executive Officer

Cheryl Sadeli, MBA, Chief Financial Officer

Laurel Lucrezia, Chief Business Development Officer

Manoel Carvalho, Director of Lab Operations

Michele Hart, Director of Marketing & Communications

Melinda Kimball, Director of Human Resources

Darlene Riordan, Director of Clinical Operations

Olga Tomashevskaya, Director of Engineering
LETTER FROM THE CEO AND BOARD CHAIR

We emerged from the pandemic disruptions of 2020 with our mission intact and ready to meet the needs of patients and doctors in new ways. In 2021, our dedicated staff found innovative ways to deliver exceptional and compassionate care, conduct groundbreaking research, and provide education to scleral eyecare professionals around the world. We are forever grateful for our team of professionals who meet the needs of those we serve every day.

In 2021, as restrictions eased, patients made their way back to eye care practitioners to get the treatment they so desperately needed. We saw patients return for PROSE® treatment in our Needham Clinic and across the PROSE Network. BostonSight SCLERAL® demand grew as we expanded our offering, and new practitioners embraced our data-driven technology while current practitioners treated new patient groups.

We are proud to play a significant role in the wider adoption of scleral lenses in the eye care industry. Our expanding international partnerships with Spectrum International in Latin America and the continued growth of LV Prasad Eye Institute in India provide greater access to the life changing solutions developed by BostonSight.

We are also pleased that 2021 saw an expansion of our PROSE Provider Network with the addition of the University of Pittsburgh Medical Center, the Ohio State University Wexner Medical Center, and Precision Cornea Centre in Ottawa, Canada, bringing us to 20 PROSE Provider Network sites in North America. PROSE treatment provides improved vision and pain relief for patients with the most complex corneal and ocular surface diseases where more widely available scleral lenses have not been successful. These patients have often lost hope of regaining functional vision and living a normal life. We are committed to increasing awareness with patients and doctors and expanding access to PROSE treatment.

BostonSight’s growth and innovations in lens technology require state-of-the-art manufacturing capabilities and equipment. We are grateful for support from the John W. Henry Foundation that enabled us to purchase a new DAC lathe. We were able to increase our manufacturing capacity and incorporate digitally based lens designs that significantly improve the efficiency of our manufacturing operations.

We significantly strengthened our governing board in 2021 by electing three members who will help us achieve our long-term goals. We thank them for their willingness to serve. Howard Purcell, OD, President and CEO of New England College of Optometry, provides a perspective into the future of optometry and education. Ron Remy, CEO of Mobile Heartbeat, brings a technology background to BostonSight's software development plans, and Marcus Hughes, Esq., Associate General Counsel at UMass Memorial Health Care, brings legal expertise in the health care field.

At BostonSight, we remained focused on our mission, no matter what the world threw at us. Your gift supports top-notch clinical care, research, education, and manufacturing quality, every day. We thank you for your support.
Our promise to patients is to provide the best sight-saving care possible. Our promise to practitioners is to empower them to deliver successful patient outcomes.

This year we received $762,982 in donations.

Your gifts support:
- the education of the public, patient, and professional eye health communities;
- research and technological innovation that advances the design, manufacturing, and application of PROSE devices and scleral lenses; and
- financial assistance to patients in need.

See what was accomplished in 2021 with YOUR support.
Thanks to generous donor support, we purchased a new DAC lathe and increased our manufacturing capacity in 2021. That became incredibly important as the demand for our lens designs has continued to grow.

In 2020, we began engineering our image-guided lens design technology, which allows practitioners with a scleral tomographer or profilometer to scan patients’ eyes and directly transmit the digital data to FitConnect®, BostonSight’s proprietary lens design and ordering platform. This year we launched that image-guided design technology, called Smart360®, which works with the OCULUS Pentacam® and Eaglet ESP. Smart360 is intended to reduce the number of device cuts and patient visits required to obtain an optimal fitting lens.

We also expanded our SmartSight HOA® program, with 25 clinicians certified to provide this advanced scleral lens design technology for patients that experience significant aberrations, including ghosting, halos, starbursts, glare, and double vision.
INNOVATION & RESEARCH

A recent analysis in Contact Lens and Anterior Eye listed BostonSight as the leading institution providing scleral lens-related peer-reviewed journal articles. This means, our work is reaching the eye care community and helping more patients.

In 2021 we published three peer-reviewed journal articles, sharing with the industry key findings on using tonometry for scleral lens evaluation, medical use of contact lenses, and the efficacy of PROSE treatment and scleral lenses in managing ocular Graft-versus-Host Disease. We see our peer-reviewed articles referenced in other providers’ articles, as well as research studies that reference our scleral lens design directly. It is an exciting time to be part of BostonSight!

Despite this, there are still many eye care professionals who are not familiar with the tremendous benefits that scleral lenses and PROSE devices have in managing ocular conditions. Through donations and community support, our research team, led by Dr. Dan Brocks, continues to push the efficacy of PROSE treatment and scleral lenses as non-surgical, non-invasive solutions that provide best quality of life with improved vision and pain relief.

This year we launched two new research studies and secured a donation of an OCULUS® AXL Wave aberrometer. BostonSight is one of only a handful of clinics in the country to have this new-to-market diagnostic machine. In addition to advancing patient care in our Needham Clinic, we are using the aberrometer for research studies, to understand how it can streamline the fitting process, and to improve our innovative HOA platform and Smart360 technologies.
After more than a year of absence, we welcomed visiting residents back to the Needham Clinic. Each year Cornea Fellows and Optometry Residents come to BostonSight for education in the latest treatments for corneal disease, and to join our medical staff in innovative clinical research on saving sight.

Our annual FitAcademy™ Retreat for Residents was held in person at the New England College of Optometry (NECO) in Boston. We rely on donor support to fund this program, which educates cornea and contact lens residents from across the country with a full weekend of didactic and wet lab training in scleral lens fitting and treatment. This is an important educational step as they embark on their careers in optometry. Our partnership with NECO only improves upon FitAcademy’s already stellar reputation.

We continued other education outreach mostly virtually, given the international nature of many of the programs.

BostonSight staff presented nine webinars and participated in nine conferences reaching thousands of attendees, including the CLASS Symposium in Latin America, British Contact Lens Association, Indian Contact Lens Program, OPTOM in Madrid, and the Global Specialty Lens Symposium.

BostonSight’s doctors were finally able to see their peers in person in the second half of 2021. All of our optometrists presented live at the American Academy of Optometry's annual meeting in Boston, and Dr. Carrasquillo presented at the International Congress of Scleral Contacts meeting in Florida.

Dr. Brocks initiated an ongoing educational seminar program for ophthalmology faculty and residents which will expand in 2022. The program’s intent is to strengthen co-managed care between optometry and ophthalmology and educate ophthalmologists on the benefits of scleral lenses for ocular surface disease management.
“I will always come here to keep my connection. It feels like coming back to my family home when I come here,” says Debby Fenn.

Debby is a PROSE patient expert. She has been wearing PROSE devices for almost 30 years and was the tenth person in the world to receive PROSE treatment.

“I’ll still never forget the first time I had a PROSE device put in. I could see the cars on Rt. 9 [a local highway]. I will never forget that for the rest of my life.”

Debby is visually impaired in her left eye, only seeing light, and has been since birth. She does not wear a device on that eye. Her right eye functioned normally but she wore a soft contact lens as a young adult to help with visual acuity.
"I remember I was living in Westchester after college, and I was having more and more trouble seeing out of my right eye. I went to an ophthalmologist who diagnosed me with keratoconus."

Keratoconus is a progressive disease where the cornea bulges into a cone-like shape, refracting light incorrectly onto the retina and distorting vision. Without treatment and management, keratoconus can lead to blindness. With one eye already compromised, Debby couldn’t let the vision in her right eye deteriorate.

Debby moved back to Boston and came to the Boston Foundation for Sight when PROSE treatment was in its infancy. She took a leave of absence from her job because she couldn’t see, but she was determined to get back to work.

“My first device fitting took 6 weeks. Putting the device on my eye took hours when I first tried. I would sit in the office and practice. But I was determined. There wasn’t an option to not do it. There wasn’t an option for me to not see. I can put my lens in asleep at this point. It’s like second nature."

Debby has been coming to BostonSight for annual checkups for years now. She considers among her “BostonSight pals” Dr. Karen Carrasquillo, and Dr. Alan Kwok, her current PROSE Provider, as well as Dr. Deborah Jacobs who previously worked for BostonSight and is now Debby’s primary cornea specialist. Her PROSE Provider, Dr. Kwok, works in partnership with Dr. Jacobs to ensure PROSE treatment is providing the necessary ocular surface management to keep her keratoconus under control.

"I’ve never been a person who focuses on what I can’t do,” she says. “I focus on what I can do. And because of PROSE, I can drive, work, run my own business, have a family, and take care of my kids. Without PROSE I would not have been able to function in the way I’ve been able to all these years.”

Debby is a licensed social worker who also ran a professional organizing business up until the pandemic. Today she focuses on social work and has been an online therapist for the past two years, along with speaking about organizing to reduce stress and help with mental health.

She has referred many patients to BostonSight over the years. If someone is worried about whether PROSE can help, I would say, “Of course you’re unsure. You’re terrified and scared. But BostonSight is a good environment to do this. What makes this place work is that the patients are well taken care of here. And look at all the success stories. Even with little kids!”

“I’m indebted for life,” she says. “I would do anything for this organization, anything.”
Sam went on a trip to Mexico for his honeymoon and saw... a blurry tropical view.

“I was so disappointed to be somewhere new and not able to see it,” he says. “Looking up at the night sky I’d see six moons instead of one.”

Sam has keratoconus. Keratoconus is a condition that affects at least 1 in 2,000 people in the U.S. It is a leading cause of corneal transplantation and a life-long disease that can cause blindness if left untreated. Keratoconus causes progressive thinning or distortion of the cornea, including a bulging cornea. This changes the corneal shape and significantly impacts vision. Symptoms can include higher order aberrations (HOAs) such as blurry vision, double vision, ghosted vision, and glare and halos around lights, as well as light sensitivity, corneal scarring, difficulty seeing at night, and eye irritation or headaches with eye pain. Both PROSE and BostonSight SCLERAL can help manage keratoconus, but choosing one solution versus the other is dependent on the severity of the condition.

In 2006, Sam moved to Boston and began seeing Dr. Samir Melki, a corneal specialist at Boston Eye Group in Brookline who manages Sam’s keratoconus. It was here at Boston Eye Group that an optometrist, who provided contact lens fittings, introduced Sam to scleral lenses. They tried a series of scleral lens brands, wearing each brand for about a year. However, none of the lenses worked well enough to improve visual acuity, comfort, blurriness, and ghosted vision.
Then, Dr. Emily Nangle at Boston Vision suggested BostonSight SCLERAL lenses. BostonSight SCLERALS were new to the market and were designed based on years of clinical patient outcomes at the BostonSight PROSE clinic in Needham, Massachusetts. Sam also has a pinguecula on each eye (a bump on the surface of the eye) complicating the lens fit. The practitioner must fit the lens so that the edge (the landing zone) does not rest harshly on the bump. When lenses land harshly over anatomical bumps on the surface, the eye develops redness (hyperemia) and there is often lens intolerance and discomfort with increased wear time.

By using a larger lens, Sam’s practitioner was able to distribute the weight of the lens so that it did not land harshly over the pingueculas, resulting in greater comfort.

Sam has been wearing BostonSight SCLERAL lenses for four years. He loves his lenses, saying, “They cover so much surface area that wind is not an issue like it was with RGPs. I no longer get dust or debris under the lens.”

He also has very dry eyes and is on a computer all day for his work in digital services.

“I would use lubricating drops at night, wake up in the middle of the night, and use them again. In the morning, I’d have to wait an hour before putting in my old scleral lenses. But with BostonSight SCLERAL, I put them in right away. They’re so comfortable, they stay in all day.”

“Nothing else has done as much for fixing the ghosting as these lenses,” Sam says. “I don’t see six moons anymore. Now I only see one and a half.”

BostonSight SCLERAL lenses are designed with a technology called SmartSight® to reduce HOAs, such as Sam’s ghosting. SmartSight is incorporated into every lens from the start and can be adjusted for each patient to provide the best possible outcome.

“Every morning I put my BostonSight SCLERAL lenses in and check my vision by looking at the roof tiles on the house across the street. The clarity is amazing. These lenses have had a profound impact on the quality of my life, and I want to get the word out about how good they are and about the work BostonSight is doing.”
In 2021, we exceeded our fundraising goal, thanks to YOU. Your support allowed us to provide financial assistance to patients in need, grow our research initiatives, and continue to educate practitioners.

**LIFETIME GIVING**

$500,000 +
- Bausch + Lomb
- John W. Henry Family Foundation

$250,000 - $499,000
- Frank and Diana Berry
- Nehemias Gorin Foundation and Gorin Family Endowment
- Bruce and Holly Johnstone
- Michael and Myra McCoy
- The Thomas Anthony Pappas Charitable Foundation
- The Samuel Rapaporte, Jr. Foundation
- Kate and Seymour Weingarten

$100,000 - $249,999
- Wendy Appel
- Harry and Honey Birkenruth
- Henry and Diane Bisgaier
- Blue Cross Blue Shield of Massachusetts Foundation
- Eugene and Irene Bonte
- Boston Eye Associates, P.C.
- The Barbara Epstein Foundation Inc.
- The Charles Evans Foundation
- Earmark
- Yuriy Fershter
- Google, Inc.
- Florence Koplow
- Lauren Marino
- Michael Nash and Carolyn Duffy
- John Pevarnik Charitable Trust
- Robert and Ruth Remis
- Robert Schaeberle
- The Abraham Shapiro Charity Fund
- Enid Starr, Esq.
- The Tonna Charitable Trust
- Geun Young Yoon
LIFETIME GIVING

$50,000 - $99,000

Lorne Abony
Helaine Allen
Warren Alpert Foundation
Evelyne Balboni
Bresky Foundation Corporation
Comenitz Family Foundation
Competitive Technologies
LeRoy and Jane Crosby
Sumner and Esther Feldberg
Paul J. Ferri
Gerald Flaxer Charitable Foundation
Howard Gorin
Allan and Anne Greenberg
John and Olga Guttag
Ann Hintlian
Johnson & Johnson
Max and Selma Kupferberg Family Foundation
Avinash and Anuja Lele
Joe Martini
Michael and Donna Moskow
OCULUS, Inc.
Larry Plotkin and Debra Yellen
Paul T. La Rocca
Michael B. Raizman
Perry Rosenthal
Howard and Carol Stoner
Alan and Ann Strassman
Paul Szczygiel
Joe and Susan Zienowicz
# 2021 Visionary Circle of Hope

## $25,000 +
- Google, Inc.
- John W. Henry Family Foundation
- Oculus, Inc.

## $10,000 - $24,999
- Henry and Diane Bisgaier
- The Barbara Epstein Foundation, Inc.
- Paul Ferri
- Joe and Susan Zienowicz

## $5,000 - $9,999
- Pamela Anderson
- Anonymous
- Michael Crowe
- Allan and Anne Greenberg
- Johnson & Johnson
- Bruce and Holly Johnstone
- Joe Martini
- Michael Nash
- Michael B. Raizman
- Julie Rutenberg

## $1,000 - $4,999
- Thomas Arnold
- Avidia Charitable Foundation
- Thelma Axberg
- Marci Azbell
- Bank of America
- Lisa Berlin
- Harry Branning
- Alicia and Glen Bunnell
- Charles and Sarah Shoaf Cabot
- CLM Fund
- J. Stephen Collins
- Wendy Cooper
- Marc and Lynne Craft
- Leroy and Jane Crosby
- Michael Daily
- Gerard De Gunzburg
- Michael Dominguez
- Gary and Susan Fentin
- Karen Grossman
- Judith Gurewich
- Gene Guselli
- Evan Haberman
- Donniel and Adina Hartman
- Shaun and Kathleen Levesque
- Michael P. and Vicki Link
- Nancy Marjollet
- Anna K. Mergen
- Latisha Middleton
- Roberta Neal
- Kelly Pucillo
- P.R. Rajagopalan
- David Rosenbloom
- John Sheskey
- George Tonna
- United Health Group
- Steven Weber
- Roger Wellington
- Sara and Jason Yost
2021 DONORS

$500 - $999

Amazonsmile Foundation
Glenn Barest
Mary Bazinet
Alyson Berliner
Jean and John Conners
Vincent Fratello
Rhonna Goodman
Elise Hauenstein
HCA Healthcare
Robert and Carolyn Hess

Elizabeth and David Hobson
Dwayne and Deborah Kepner
Charles and Joan Killilea
Daniel and Joyce Kogut
Regeneron Pharmaceuticals, Inc.
Charles Rehn
Ron Remy
Joel Rosenthal
Matthew Teague
Sanjay Varma

$499 and below

Rosa Abney
Rao Addanki
Deanne Aguirre
Virginia Alden
Marcia Allar
Steven Appel
Kevin Atkinson
Norman and Monique Avey
Ana Azeredo
Tamara Bailey
David Baltisberger
Linda Barocas
Dawn Bent
Jenni Bergman
Patricia Bergmann
Sandra Berinato
Steven Berliner
Gio Bianchini
Todd Birkenruth

James Bond
Andrea Bonte Arcuri
Robert Bower
Joann Bowman
Jack and Nancy Brennan
Paula Breslin
Marie Britt
Maurice Brown
Jeanne Bruno
Nancy Busby
Lorrie Busse
Patricia Byrne
Pamela Cacace-Crepeau
Cindy Carlson
Karen Carrasquillo
John Champion
Carroll and Raymond Charette
Victoria Chiu-lin
Vera Claire
2021 DONORS

$499 and below

Angela Coccaro-Fischer
Iva Colgan
Ross Connelly
Dennis and Jillian Corkum
Patricia Cortesa-O'donovan
Susan Costello
Carol and Timothy Reed Counihan
Randy and Eloise Covalt
Stephanie Craig
Kimberly Cyr
John Delude
William and Deborah Dennett
Camden Di Carlo
Patricia Donahue Hageman
Sean and Sarah Dorfman
Michael Dorsett
Roberta Drury
Robert Dunnigan
Julie Echols
Bernard and Lois Edinberg
Erin Elliott
Stephen English
Norman and Mary Jo Everett
Dan and Catherane Faucher
Naiomi Fernandes-Pucillo
William Finklea
Mark and Lesley Finn
Jeanette Flores
Bernard Fried
David Friend
Anthony Fucillo
Betty Gallardo

Isabelle Garreaud
Kim Gavrauda
John Geisler
Judy Geleerd
Christie Geotis
Natalie Getsey
Donna Gilbert
Dianne Giles
Edward Ginsburg
Inez Greco
Gary Green
Lydia and Ron Greenfield
Peter Greven
Dorothy Grodberg
Michele Hart
Savannah Hastey
Kenneth Hengeli
Jeb and Miloslava Hensley
Elizabeth Hinkle
Connie Ho
Lois Horowitz
Chris Horton
Mary Hough
Linda Howey
Barry Hyman
Jeannette lles
Douglas and Edythe Jablonsky
Kathy Jack
Deborah S. Jacobs
Joy Jennings
Klavs Jensen
Peter Jones
2021 DONORS

$499 and below

Shannon Jones  
David and Marcia Jordan  
Michael Kane  
Adolph Karchmer  
Alexandra Kaspin  
Joel Katz  
Leslie Kaufman  
Sonia Ketkar  
Melinda Kimball  
Connie King  
Brandon Kleeman  
Andrea Knight  
Ilene Knopping  
Gregory Kohl  
Robert Kopelman  
Ilana Kraus  
Irma Landsberger  
Linda Large  
Melissa Lasky  
Keng Lee  
Susan Legrand  
Klimenty Levin  
Marianne Levine  
Martin and Sandra Levy  
Stephen Limon  
Hilaire Linn  
Vicki Little  
Laura Loop  
Laurel Lucrezia  
Kenneth Lundeen  
Jennifer MacDonald  
Mark Maciolek  

Roger and Deborah Mahair  
Michele Malgieri  
Raymond and Mary Marble  
Andrea Martin  
Linda Martin  
Matthew and Margarethe Mashikian  
Daniel and Sheila Massarelli  
Mark and Catherine Mathers  
Jason and Shoshana Mavor  
Jack Mayer  
Mark and Sandra Mazur  
Karen McAnern  
Joseph McKeon  
David McMullin  
Louise Melinn  
Robert and Donna Metafora  
Richard Metcalfe  
Kalvin and Jan Milan  
Nancy Miller  
Thomas Mills  
Veekey Moy  
Peter Muise  
William and Rita Needel  
Carlos Neu  
Jeffrey Nicolini  
Diane Norton  
Kevin O'Donovan  
Eli Okrant  
Colter Oliveira-McDaniel  
Jill Olsen  
Barbara Oravec  
John Owen
2021 DONORS

$499 and below

Charles W. Paepke
Ilaria Pagano
Martha Paleski
Eltha Palmer
Emily Papworth
Gina Parkinson
Lisa Paschal
Paul Pavljuk
Pedro Payano
Paypal Giving
Beverly Peiser
Toni Pepe
Sarait Peralta
Teri Piatt
Ellen Pichey
Tamela Pink
Michael Pucillo
Roisin Pucillo
Bernadette Pucillo
Megan Pucillo
Jennifer Pucillo-Mott
Christopher Quental
Gerry Radzanowski
Noel Ramos
Don Rank
Lauren Raschke
Anne Redman-Lyon
Nolan Regan
Rose Reyes
David Rich
Humberto Rios
Marco Rios

Jorge Rios
Eunice Roberts
Martin Rogers
Laura Roman
Bruno and Victoria Rondinelli
Shannon Ross
Barbara Rostosky
Todd and Sheila Roth
James Ruby
Nicole Ruser
T. Michael Russo
Nicholla Sacks
Akhtar Samani
Patricia Schmidt
Patricia Searels
Ruchika Sethi
Robert Seyler
Sandra Shapiro
John Shea
Donna Sherman
Barbara Sherwood
Emily Sira
Paul Skiver
Jonathan Slade
Loni Smith
Darlene Smolak
Julie Spencer
Rosalind Spigel
Susan Spilberg
Doreen Squillace
Robert Strom
Noelle Sun
2021 DONORS

$499 and below

Alfred Thoman
David Ting
Bill Tolles
Carla Tome
Robert VanGrol
Tatleen Vassell
Reynaldo Vega-Vargas
Paul Villers
Jean Vnenchak
Jeanne Walker
Jane Walters
William Ward
Connie and Larry Webb
Jonathan Weber
Jerome Weinstein
Irwin Weiss
Rita and Wyatt Wells
Norman Wilikofsky
Lorraine Willett
James Willis
Janice Wilson
John Wilson
Manira Wilson-Bassett
William Wright
Daniel Wywoda
Craig Yarnell
F. Zeiss
Jodi Zimmerman

Thank you
### INCOME AND EXPENSES ($ in 000's)

<table>
<thead>
<tr>
<th></th>
<th>12/31/2021</th>
<th>12/31/2020</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>INCOME</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Network clinic revenue</td>
<td>$3,640</td>
<td>$2,410</td>
</tr>
<tr>
<td>Patient services</td>
<td>3,086</td>
<td>2,534</td>
</tr>
<tr>
<td>Contributions and grants</td>
<td>1,363</td>
<td>1,173</td>
</tr>
<tr>
<td>In-kind and other</td>
<td>235</td>
<td>95</td>
</tr>
<tr>
<td><strong>Total Income</strong></td>
<td>$8,324</td>
<td>$6,212</td>
</tr>
<tr>
<td><strong>EXPENSES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Operating, research, education and teaching</td>
<td>6,140</td>
<td>5,174</td>
</tr>
<tr>
<td>General and administrative</td>
<td>1,148</td>
<td>1,024</td>
</tr>
<tr>
<td>Fundraising</td>
<td>81</td>
<td>124</td>
</tr>
<tr>
<td><strong>Total Expenses</strong></td>
<td>$7,368</td>
<td>$6,322</td>
</tr>
<tr>
<td><strong>Net Income</strong></td>
<td>$956</td>
<td>$(110)</td>
</tr>
</tbody>
</table>

The information has been extracted from the IRS form 990 and the financial statements of the Boston Foundation for Sight for the years ending December 31, 2020 and 2021 that were audited by the independent certified public accounting firm AAFCPAs.
## BALANCE SHEET ($ in 000's)

### ASSETS

<table>
<thead>
<tr>
<th>Asset</th>
<th>12/31/2021</th>
<th>12/31/2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and cash equivalents</td>
<td>$2,788</td>
<td>$2,032</td>
</tr>
<tr>
<td>Current portion of restricted cash</td>
<td>62</td>
<td>23</td>
</tr>
<tr>
<td>Accounts Receivable - patients</td>
<td>639</td>
<td>758</td>
</tr>
<tr>
<td>Accounts Receivable - network clinics</td>
<td>754</td>
<td>317</td>
</tr>
<tr>
<td>Grants and other receivables</td>
<td>90</td>
<td>134</td>
</tr>
<tr>
<td>Inventory</td>
<td>288</td>
<td>359</td>
</tr>
<tr>
<td>Prepaid expenses and other</td>
<td>77</td>
<td>69</td>
</tr>
<tr>
<td><strong>Total current assets</strong></td>
<td><strong>$4,697</strong></td>
<td><strong>$3,691</strong></td>
</tr>
</tbody>
</table>

**Other assets:**

<table>
<thead>
<tr>
<th>Asset</th>
<th>12/31/2021</th>
<th>12/31/2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Property and Equipment, net</td>
<td>1,409</td>
<td>1,278</td>
</tr>
<tr>
<td>Restricted Cash</td>
<td>185</td>
<td>185</td>
</tr>
<tr>
<td>Deposits</td>
<td>33</td>
<td>33</td>
</tr>
<tr>
<td><strong>Total assets</strong></td>
<td><strong>$6,324</strong></td>
<td><strong>$5,186</strong></td>
</tr>
</tbody>
</table>

### LIABILITIES AND NET ASSETS

#### Current liabilities:

<table>
<thead>
<tr>
<th>Liability</th>
<th>12/31/2021</th>
<th>12/31/2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accounts Payable and accrued expenses</td>
<td>$812</td>
<td>$656</td>
</tr>
<tr>
<td>Current portion of note payable</td>
<td>95</td>
<td>91</td>
</tr>
<tr>
<td>Deferred revenue</td>
<td>604</td>
<td>490</td>
</tr>
<tr>
<td><strong>Total current liabilities</strong></td>
<td><strong>$1,512</strong></td>
<td><strong>$1,236</strong></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Liability</th>
<th>12/31/2021</th>
<th>12/31/2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Note Payable, net of current portion</td>
<td>172</td>
<td>265</td>
</tr>
<tr>
<td><strong>Total liabilities</strong></td>
<td><strong>$1,683</strong></td>
<td><strong>$1,501</strong></td>
</tr>
</tbody>
</table>

#### Net assets:

<table>
<thead>
<tr>
<th>Category</th>
<th>12/31/2021</th>
<th>12/31/2020</th>
</tr>
</thead>
<tbody>
<tr>
<td>Without donor restrictions</td>
<td>4,394</td>
<td>3,477</td>
</tr>
<tr>
<td>With donor restrictions</td>
<td>247</td>
<td>208</td>
</tr>
<tr>
<td><strong>Total net assets</strong></td>
<td><strong>$4,641</strong></td>
<td><strong>$3,685</strong></td>
</tr>
</tbody>
</table>

**Total liabilities and net assets:**

<table>
<thead>
<tr>
<th>Category</th>
<th>12/31/2021</th>
<th>12/31/2020</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total liabilities and net assets</strong></td>
<td><strong>$6,324</strong></td>
<td><strong>$5,186</strong></td>
</tr>
</tbody>
</table>